WO2006035445A3 - Methods of treating pathologies associated with oxidative stress - Google Patents

Methods of treating pathologies associated with oxidative stress Download PDF

Info

Publication number
WO2006035445A3
WO2006035445A3 PCT/IL2005/001052 IL2005001052W WO2006035445A3 WO 2006035445 A3 WO2006035445 A3 WO 2006035445A3 IL 2005001052 W IL2005001052 W IL 2005001052W WO 2006035445 A3 WO2006035445 A3 WO 2006035445A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxidative stress
methods
treating pathologies
pathologies associated
treating
Prior art date
Application number
PCT/IL2005/001052
Other languages
French (fr)
Other versions
WO2006035445A2 (en
Inventor
Oron Yacoby-Zeevi
Iris Pecker
Original Assignee
Insight Biopharmaceuticals Ltd
Oron Yacoby-Zeevi
Iris Pecker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Biopharmaceuticals Ltd, Oron Yacoby-Zeevi, Iris Pecker filed Critical Insight Biopharmaceuticals Ltd
Publication of WO2006035445A2 publication Critical patent/WO2006035445A2/en
Publication of WO2006035445A3 publication Critical patent/WO2006035445A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Methods of protecting cells from oxidative stress or damage and for treating pathologies or conditions associated with oxidative stress are provided. Specifically, the present invention discloses the use of agents capable of upregulating the expression level and/or activity of an ECM degrading enzyme for the treatment of oxidative stress related pathologies or conditions.
PCT/IL2005/001052 2004-09-29 2005-09-29 Methods of treating pathologies associated with oxidative stress WO2006035445A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61370804P 2004-09-29 2004-09-29
US60/613,708 2004-09-29

Publications (2)

Publication Number Publication Date
WO2006035445A2 WO2006035445A2 (en) 2006-04-06
WO2006035445A3 true WO2006035445A3 (en) 2006-08-31

Family

ID=36119283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2005/001052 WO2006035445A2 (en) 2004-09-29 2005-09-29 Methods of treating pathologies associated with oxidative stress

Country Status (1)

Country Link
WO (1) WO2006035445A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042190A4 (en) * 2006-05-19 2012-05-30 Aichi Prefecture Ameliorating agent for brain damage
JP2009234916A (en) * 2006-07-24 2009-10-15 Stelic Institute Of Regenerative Medicine Insulin resistance reducer based on chondroitin sulfate proteoglycan accumulation regulation
JP4101276B2 (en) * 2006-08-25 2008-06-18 株式会社ステリック再生医科学研究所 Chronic obstructive pulmonary disease improving agent
JP2009292725A (en) * 2006-09-01 2009-12-17 Stelic Institute Of Regenerative Medicine Kidney disease-improving agent
WO2008029493A1 (en) * 2006-09-08 2008-03-13 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Nerve fiber degeneration inhibitor
DE102007054877A1 (en) * 2007-11-15 2009-05-20 Dieter Dr. med. Wetzel Use of hyaluronidase e.g. as a drug for the treatment of profibrotic metabolic disorder, fibrotic liver disease, chronic viral liver disease, portal hypertension, chronic hepatitis C and hepatocellular carcinoma
JP2013522172A (en) * 2010-03-12 2013-06-13 ジ オーストラリアン ナショナル ユニバーシティ Heparan sulfate replacement therapy
WO2012071420A1 (en) * 2010-11-23 2012-05-31 The Trustees Of Columbia University In The City Of New York Enzyme combinations to reduce brain tissue swelling
WO2014065669A1 (en) * 2012-10-26 2014-05-01 Stichting Vu-Vumc Methods of treatment and diagnosis for cognitive decline and memory impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002977A1 (en) * 1989-08-23 1991-03-07 Hadassah Medical Organization Wound healing preparations containing heparanase
US6733981B2 (en) * 1994-11-01 2004-05-11 Human Genome Sciences, Inc. Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002977A1 (en) * 1989-08-23 1991-03-07 Hadassah Medical Organization Wound healing preparations containing heparanase
US6733981B2 (en) * 1994-11-01 2004-05-11 Human Genome Sciences, Inc. Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4

Also Published As

Publication number Publication date
WO2006035445A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2006035445A3 (en) Methods of treating pathologies associated with oxidative stress
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
UA98629C2 (en) Compounds and methods for kinase modulation
WO2007030567A3 (en) Pparactive compounds
NL1025071A1 (en) Compounds for the treatment of abnormal cell growth.
WO2006105304A3 (en) Phenyl and pyridyl lta4h modulators
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2003101397A3 (en) Tetravalent dengue vaccines
WO2008054676A3 (en) Medical devices and methods of using the same
WO2005068421A8 (en) Prostaglandin nitrooxyderivatives
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
TW200736253A (en) Pyridopyrazine derivatives and their use
WO2006128142A3 (en) Inhibitors of cytosolic phospholipase a2
WO2005117938A3 (en) Methods of treating ocular conditions
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
AU2003250666A1 (en) Stem cells for treating pancreatic damage
AU2002953327A0 (en) Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
NL1029045A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
WO2007019312A3 (en) Methods for characterizing and treating cognitive impairment in aging and disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase